Richard B Warren
Overview
Explore the profile of Richard B Warren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
3177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gooderham M, Molin S, Bissonnette R, Worm M, Crepy M, Stingeni L, et al.
J Am Acad Dermatol
. 2025 Mar;
PMID: 40081663
Background: There are no topical treatments that have been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE). Objective: To evaluate the long-term safety and efficacy of...
2.
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, et al.
J Eur Acad Dermatol Venereol
. 2025 Mar;
PMID: 40045918
Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for...
3.
Phan D, Bewley A, Laws P, Mackenzie T, Smith C, Griffiths C, et al.
JAMA Dermatol
. 2025 Mar;
PMID: 40042863
Importance: The uncertainties about the real-world effectiveness of adalimumab biosimilars limit their widespread adoption for psoriasis. Objective: To compare the effectiveness of adalimumab biosimilars Amjevita and Imraldi with Humira for...
4.
Warren R, Weiss A, Felding J, Sommer M
Dermatol Ther (Heidelb)
. 2025 Mar;
PMID: 40042770
Introduction: Orismilast is a novel oral selective inhibitor of phosphodiesterase 4B and 4D subtypes (PDE4B/D) in clinical development for treatment of atopic dermatitis (AD) and other inflammatory skin conditions. Herein,...
5.
Phan D, Lunt M, Warren R, Yiu Z
J Eur Acad Dermatol Venereol
. 2025 Mar;
PMID: 40026268
No abstract available.
6.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
Nat Commun
. 2025 Feb;
16(1):2051.
PMID: 40021644
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
7.
Gribaleva E, Chan K, Chivardi Moreno C, Prieto Merino D, Tsoi M, Carroll R, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39876781
No abstract available.
8.
Warren R, Lebwohl M, Thaci D, Gooderham M, Pinter A, Paul C, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39862230
Background: Overexpression of interleukin (IL)-17A and IL-17F significantly influences psoriasis pathology. Until recently, biologics targeting IL-17A alone, like secukinumab, were used to treat psoriasis. Bimekizumab is a monoclonal IgG1 antibody...
9.
Silverberg J, Eichenfield L, Blauvelt A, Irvine A, Guttman-Yassky E, Langley R, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39847538
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety...
10.
Warren R, Pavlovsky L, Costanzo A, Bukhalo M, Korman N, Huang Y, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(2):477-481.
PMID: 39821856
No abstract available.